Novel Cancer Vaccine Prevents Melanoma From Returning in First for mRNA
- On Wednesday, Moderna and Merck announced their personalized mRNA vaccine intismeran combined with Keytruda met primary and secondary endpoints in a Phase 3 trial of 1,137 high-risk melanoma patients.
- Designed to target unique mutations in each patient's tumor, intismeran trains the immune system to identify and destroy remaining cancer cells as an adjuvant therapy administered after surgery.
- Shares of Moderna surged 93% on Wednesday after the vaccine-plus-Keytruda combination demonstrated superior efficacy in preventing melanoma recurrence and spread compared with Keytruda alone in the late-stage study.
- Merck and Moderna plan to present detailed trial results at an upcoming medical meeting and share findings with regulators, having already secured an expedited review pathway from the FDA and European Medicines Agency.
- Manufacturing each personalized dose takes six weeks, while companies explore this mRNA approach across nine additional Phase 2 and Phase 3 trials spanning melanoma, lung, bladder, kidney, pancreatic and gastric cancers.
183 Articles
183 Articles
The actions of Moderna fly to Wall Street after the positive results of the phase 3 study on mRNA vaccine against melanoma developed together with Merck. The title of the American biotech company has come to gain over 130%, exceeding 145 dollars, while Merck, partner of the project and producer of Keytruda immunotherapy, has [...] The article "Results promising" for mRna vaccine against the recurrence of melanoma. The actions of Moderna fly on t…
Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial
Stock photo of a doctor examining a patient’s skin. (Lordhenrivoton/STOCK PHOTO/Getty Images) (NEW YORK) — Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma. The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending mel…
Moderna Shares Double Overnight Because a Made-to-Order mRNA Vaccine Actually Beats Skin Cancer
Moderna shares surged in pre-market trading after the US biotech announced that its personalised mRNA cancer vaccine, intismeran, showed a statistically significant reduction in melanoma recurrence in a late-stage clinical trial. The news, released on Wednesday, sent Moderna's stock soaring by more than 100 per cent in early trading as investors reacted to what some analysts described as a potentially significant development in personalised canc…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
